Mona Fouad received The Vilcek Foundation and The Arnold P. Gold Foundation’s 2022 Vilcek-Gold Award for Humanism in Healthcare.
Chris Neumann was named vice president of learning and education, and Kirsta Suggs the first director of diversity, equity, and inclusion, at the American Society for Radiation Oncology.
ASTRO delivered comments to the Centers for Medicare and Medicaid Services in response to the agency’s proposed rule that would indefinitely postpone the start of an alternative payment model for radiation oncology.
Aerobic exercise reprograms the immune system to reduce pancreatic tumor growth and amplify the effects of immunotherapy, according to a study led by researchers at NYU Grossman School of Medicine and Perlmutter Cancer Center.
Researchers at the Johns Hopkins Kimmel Cancer Center and the Johns Hopkins Bloomberg School of Public Health found that secreted age-induced changes in distant sites such as the lung can effectively reactivate dormant tumor cells and cause them to grow.
Researchers at VCU Massey Cancer Center identified a novel, protein-based combination therapy through which tumor resistance can be overcome to more effectively treat colorectal cancer.
Researchers at Roswell Park Comprehensive Cancer Center found that mitochondrial unfolded protein response—a unique longevity function of mitochondria—could be a target for the treatment and management of metastatic, resistant, or recurrent prostate cancer.
Researchers at the American Cancer Society found that parental cancer is associated with a greater likelihood of family-level food insecurity, financial worry about housing costs and other monthly bills, and transportation barriers to medical care for children in the United States.
Researchers at ACS showed that the mortality risk from cardiovascular disease differs considerably among cancer survivors by race/ethnicity and cancer types.
In a study of more than 1,500 patients with high-risk renal cell carcinoma, those who took the drug everolimus daily for up to one year after surgery lived longer without their disease returning than those who did not take everolimus. Improvement was seen primarily in patients with very high-risk disease, while patients with intermediate high-risk disease saw no improvement in recurrence-free survival.
